| 江 波,周 伟,龙翔宇,朱其荣,应 伟.奥沙利铂联合5-氟尿嘧啶对食管癌患者血清IGF-1及TGF-β1水平的影响[J].,2017,17(20):3940-3943 |
| 奥沙利铂联合5-氟尿嘧啶对食管癌患者血清IGF-1及TGF-β1水平的影响 |
| Effects of Oxaliplatin and 5-Fluorouracil on Serum Levels of IGF-1 and TGF-β1 in Patients with Esophageal Carcinoma |
| 投稿时间：2016-12-28 修订日期：2017-01-23 |
| DOI：10.13241/j.cnki.pmb.2017.20.033 |
| 中文关键词: 奥沙利铂 5-氟尿嘧啶 食管癌 胰岛素样生长因子1 转化生长因子β1 |
| 英文关键词: Oxaliplatin 5-fluorouracil Esophageal cancer Insulin-like growth factor-1 Transforming growth factor-β1 |
| 基金项目:四川省卫生厅基金项目 (981023) |
|
| 摘要点击次数: 350 |
| 全文下载次数: 199 |
| 中文摘要: |
| 摘要 目的：研究奥沙利铂联合5-氟尿嘧啶对食管癌患者的治疗效果及对血清胰岛素样生长因子1（IGF-1）及转化生长因子β1（TGF-β1）的影响。方法：选取2014年9月至2015年8月本院收治的78例食管癌患者，根据随机数字法分为观察组和对照组，39例每组。观察组采取奥沙利铂联合5-氟尿嘧啶进行治疗，对照组采取顺铂联合5-氟尿嘧啶进行治疗。比较两组患者治疗前后IGF-1、TGF-β1水平变化，分析两组患者临床疗效和不良反应。结果：治疗后，观察组总缓解率显著高于对照组（P<0.05）；两组患者IGF-1、TGF-β1水平较治疗前显著降低（P<0.05），观察组IGF-1、TGF-β1水平低于对照组（P<0.05）；两组患者白细胞降低、血小板减少、贫血、脱发、神经感觉障碍、神经运动障碍不良反应率比较，差异无统计学意义（P>0.05）；观察组患者恶心呕吐、口腔炎、腹泻等不良反应发生率均低于对照组（P<0.05）。结论：奥沙利铂联合5-氟尿嘧啶方治疗食管癌的临床疗效显著，能够有效降低患者血清TGF-β1及IGF-1水平，且不良反应少，安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of oxaliplatin combined with 5-fluorouracil on serum levels of insulin-like growth factor-1 (IGF-1) and transforming growth factor-β1 (TGF-β1) of patients with esophageal cancer. Methods: 78 patients with esophageal cancer who were treated in our hospital from September 2014 to August 2015 were selected and randomly divided into the observation group and the control group with 39 cases in each group. The patients in the observation group were treated with oxaliplatin and 5-fluorouracil, and the patients in the control group were treated with cisplatin combined with 5-fluorouracil. Then the serum levels of IGF-1 and TGF-β1, the clinical efficacy and adverse reactions in the two groups were observed and compared before and after the treatment. Results: After treatment, the total remission rate in the observation group was significantly higher than that of the control group (P<0.05). After treatment, the serum levels of IGF-1 and TGF-β1 in the two groups were significantly lower than before (P<0.05). The serum levels of IGF-1 and TGF-β1 in the observation group were significantly lower than those of the control group (P<0.05). There was no significant difference in the incidence of eukopenia, thrombocytopenia, anemia, alopecia, neurosensory disorder and neuromotor disorder between the two groups (P>0.05). The adverse reactions of nausea, vomiting, stomatitis and diarrhea in the observation group were significantly lower than those of the control group (P<0.05). Conclusion: Oxaliplatin combined with 5-fluorouracil regimen can reduce the serum levels of TGF-β1 and IGF-1 in patients with esophageal cancer, with obvious clinical efficacy and safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
